News
21mon MSN
GLP-1 drugs such as Lilly’s Mounjaro and Novo’s Ozempic linked to lower cancer risk: study
GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and Ozempic, developed by Novo Nordisk (NVO), can reduce cancer risk, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback